Manufacturing USA® Pandemic Response and NIIMBL Update

Visiting Committee on Advanced Technology June 9, 2020

Mike Molnar NIST Office of Advanced Manufacturing Kelvin Lee National Institute for Innovation in Manufacturing Biopharmaceuticals

National Institute of Standards and Technology U.S. Department of Commerce

The NIIMBL community responded rapidly to a call to action

Friday, April 3, 2020 – 10:30am email with a request for proposals

Friday, April 3, 2020 – 2:00pm webinar on our process

Monday April 6, 2020 – 3:00pm deadline for submissions

Submissions accepted only from NIIMBL Members, but <u>not limited</u> to biopharmaceutical manufacturing technologies.

We received well over 200 submissions in response to our request:

Small businesses Large, global companies Universities and Academic Medical Centers Federal scientists etc

Going through a process now to finalize which projects will launch.





How the NIIMBL Community Can Contribute

- Testing antibody, PCR, other
- Contact tracing, technologies associated with tracking for people, equipment, etc.
- Decontamination technologies
- PPE (development, manufacturing, etc.)
- Medical countermeasures* discovery, development, manufacturing
- Supply chain analysis, modeling, including financial impact forecasting
- Medical equipment (development, manufacturing)
- Other

*Medical countermeasures included small molecules, large molecules, cell therapies, vaccines, and plasma therapies





\$9 million NIST Award for NIIMBL Projects



Provide virus proteins to improve blood testing capabilities Assist regional hospital systems with validation of rapid in-house diagnostic testing capabilities

Identify alternative domestic supply chains to reduce foreign dependence for respirators and masks Validate the use of environmental decontamination approaches for clinical spaces Develop automated contact tracing technology w/i facilities to limit the spread of coronavirus in essential workers

Accelerate development of more flexible manufacturing platforms of biologic therapies and rapid release testing

Images: Adobe Images



©2020 NIIMBL | CONFIDENTIAL | For Authorized Use Only

Other Developments from NIIMBL



Membership growth continues

An initiative related to workforce

An initiative related to technology

Other recent news







©2020 NIIMBL | CONFIDENTIAL | For Authorized Use Only




NIIMBL status – 3 years post-launch

Ecosystem -150 + members 10 major manufacturers and OEMs > 40% industry 24 premier research institutions 6 federal agencies 4 MEPs

Impacts

\$63 M project portfolio awarded > \$9 M workforce development 3 Roadmaps published, 2 streams ongoing 3 'NIIMBL led' industry-wide programs to launch in 2020



Actual coinvestment (as of Feb 2019) 2.12 to 1 match



Planned over NIST award 1.84 to 1 match





Highlights and Activities | NIIMBL eXperience



Building a highly-skilled and diverse workforce pipeline

- 5 students participated from Florida A&M University, Howard University, Delaware State University and University of Massachusetts Dartmouth
- Learning goals
 - Explore career paths in biopharmaceutical manufacturing
 - Awareness of internship and training opportunities
 - Networking with career professionals and mentoring
 - Develop a personal brand statement and practice execution

Industry and Federal Agency Participants:









Networking and personal branding from NSBE



Manufacturing tour at Merck



Hearing "how I did it" from career professional



Hands on at Amgen's Immersive Research Center

NØMBL

©2020 NIIMBL | CONFIDENTIAL | For Authorized Use Only

Distinguished R&D and supply chain technical leaders from 14 major manufacturers & suppliers met and agreed:

- Significant opportunity to impactfully transform CMC development & manufacturing through E2E integration and technology advancement.
- Collaboration in consortium will significantly accelerate transformation
- Success enabled by expertise, leadership & capability of committed industry leaders
- We will advocate for <u>our</u> companies to participate
- High level goals/strategy agreed: priorities/details to be refined after participants identified

Organization	Title
Amgen	Scientific Director, Technology & Engineering
AstraZeneca	Head Bioprocess Technology & Engineering
BMS	Head of Biologics MS&T
Eli Lilly	Research Advisor
FDA	Deputy Director, OBP, CDER, FDA
NIST	Technical Program Manager, NIIMBL
GSK	Sr. Director, MS&T
Janssen	Sr. Dir. API Large Molecule Dev & Man. Sci.
Just	Director
Merck & Co	AVP Biologics Process R&D
	Principal Scientist
EMD/Millipore	Director, Next Generation Processing R&D
Novartis	Head, Advanced Process & Technology Biologics
Pfizer	Vice President, Technology & Innovation Strategy
Roche	Head of Biologics for Tomorrow
Sanofi	Senior Scientist
Sartorius	Head of Advanced Materials & Processing



Vision: By 2029 invent, design, build and commercialize drug substance and product manufacturing capability enabling:

- Flexibility to supply extremely diverse and changing portfolio of products in the face of uncertainty and changing demand
- Improved Control, Robustness and Security of Supply
- Faster Product Development and Supply Chain Velocity
- Sustainable plastic and energy use
- Capital & Operating Cost dramatically reduced
 - No longer barrier to availability of capacity, innovation or change
- DS & DP expertise and thinking integrated vial to vial



The image we used to use...




New NIIMBL HQ Opening Q1 2020 225,000 gsf













©2020 NIIMBL | CONFIDENTIAL | For Authorized Use Only

12

AMERICAN INNOVATION AT WORK NIMMBL


Buffer Stock Blending Skid













©2020 NIIMBL | CONFIDENTIAL | For Authorized Use Only